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Abstract: Ten biologically active 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione derivatives were synthesized and 
their structures were confirmed by IR, 1H and 13C NMR spectroscopy and mass spectrometry. Synthesized compounds were scanned for their 
antioxidant, antimicrobial and antiproliferative activity. Antibacterial activity was tested by the diffusion and dilution method against Bacillus 
subtilis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa, while antifungal activity was tested against Candida albicans and 
Saccharomyces cerevisiae. Antiproliferative activity was tested against HeLa (cervical carcinoma), SW620 (colorectal adenocarcinoma, 
metastatic), hepatocellular carcinoma (HEpG2), lung carcinoma cells (A549) and mouse embryo fibroblast cell line (3T3). The best antioxidant 
activity showed compound 2 with two hydroxy groups substituted on phenyl ring in positions 2' and 3'.  The best antimicrobial activity of all 
synthesized compounds showed compound 8, while the best antiproliferative activity showed compound 6. Results signify the importance of 
xanthene-1,8-dione derivatives as potential antioxidant and antiproliferative agents. 
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INTRODUCTION 
ANTHENES and its derivatives are known as an 
important class of heterocyclic compounds that have 
been widely used as leuco dyes, pH sensitive fluorescent 
materials for visualization of biomolecules and in laser 
technologies due to their spectroscopic properties.[1] Also, 
xanthenes constitute as an important class of biologically 
active compounds due to their broad spectrum of pharma-
cological activities such as antibacterial,[2] antiviral,[3] anti-
inflammatory activities.[4] Natural and synthetic xanthene 
derivatives are also well-known for their ability to act as 
antioxidants and/or enzyme inhibitors.[5] Due to their wide 
range of applications, these compounds have received a 
great deal of attention regarding their synthesis. A wide 
variety of methods for the preparation of the xanthenes 
have been reported.[6–11] 
 Antioxidants are necessary to control degenerative 
reactions produced by reactive oxygen and nitrogen spe-
cies. These species are involved in several ailments includ-
ing cancer, heart diseases and Alzheimer’s disease.[12] 
 With the development of new strains of bacteria re-
sistant to many currently available antibiotic treatments, 
there is increasing interest in the discovery of new antibac-
terial agents. Antimicrobial resistance refers to microor-
ganism that have developed the ability to inactivate, 
exclude or block the inhibition or lethal mechanism of the 
antimicrobial agents.[13] 
 In our previous work we prepared thirteen 2,2,5,5-
tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-
1,8(2H)-dione derivatives using reliable one-pot synthesis 
followed by structure elucidating measurements, and per-
formed in vitro antimicrobial potency evaluation against 
Escherichia coli and Candida albicans strains.[14] Antimicrobial 
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and antiproliferative studies on similar xanthenes were 
reported,[15–18] however none so far on these particular 
derivatives. Presented study therefore, was aimed to 
prepare new derivatives and evaluate their antimicrobial, 
antiproliferative and antioxidant activity. 
 
EXPERIMENTAL 
Instrumentation 
Melting points of the compounds were determined with 
BŰCHI Melting Point B-545 and are presented uncorrected. 
Infrared (IR) spectra of synthesized compounds were rec-
orded by Shimadzu IR Prestige 21 ID using KBr pellets. The 
1H and 13C nuclear magnetic resonance (NMR) spectra were 
recorded at 600 and 150 MHz, respectively, in CDCl3 at 25 
°C using NMR spectrometer Bruker AV600, with tetrame-
thylsilane (TMS) as internal reference. Chemical shifts (δ) 
are reported in ppm and coupling constants (J) in Hz. Ele-
mental analyses of synthesized compounds were recorded 
by Vario EL III C, H, N, S/O Elemental Analyzer, Elementar 
Analysensysteme GmbH, Hanau-Germany. Electrospray ioni-
zation mass spectrometry (ESI-MS) measurements were per-
formed on a high performance liquid chromatography–mass 
spectrometry (HPLC-MS) triple quadrupole 6420 instrument 
equipped with an autosampler (Agilent Technologies, Palo 
Alto, CA, USA). The desolvation gas temperature was 300 °C 
with flow rate of 6.0 L min–1. The fragmentor voltage was  
135 V and capillary voltage was 4.0 kV. Mobile phase was  
0.1 % formic acid in 50 % methanol and a flow rate of mobile 
phase was 0.2 mL min–1. 
General Procedure for Synthesis 
A mixture of substituted benzaldehyde (1 mmol),  
5,5-dimethylcyclohexane-1,3-dione (2 mmol) and DABCO 
(10 mmol %) in H2O (20 mL) was refluxed for 30 min. The 
progress of the reaction was monitored by TLC by using sil-
ica gel 60G F254 plates and dichlormethane : hexane = 1 : 1 
as the mobile phase. After completion of the reaction, the 
mixture was cooled to room temperature, and the solid was 
filtered off and washed with distilled water. The crude 
product was purified by recrystallization from 96 % 
ethanol.[19] 
 Analytical data for synthesized 2,2,5,5-tetramethyl-
9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-diones 
are listed below. 
 
2,2,5,5-TETRAMETHYL-9-(2',3'-DIHYDROXYPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (1) 
77.25 %; m.p 214–217 °C; IR(KBr) νmax / cm–1: 3200–3400 
(Ar–OH), 3000 (Ar–H), 1670 (C=O), 1300 (C–O), 1500 (C=O), 
1200 (Ar–OH), 1152 (C–O–C); 1H NMR (CDCl3) δ / ppm: 1.01 
(s, 3H, H-17), 1.04 (s, 3H, H-15), 1.08 (s, 6H, H-14 and H-16), 
1.88–2.72 (m, 10H, H-3, H-5, H-9, H-11 and 2’-OH), 4.67 (s, 
1H, H-13), 6.54 (dd, 1H, J4′5′ = 7.6 Hz, J4′6′ = 1.1 Hz, H-4′), 6.75 
(dd, 1H, J5′6′ = 8.1 Hz, J4′6′ = 1.4 Hz, H-6′), 6.88 (t, 1H, J5′6′ = 
7.9 Hz, J4′5′ = 7.8 Hz, H-5′); 13C NMR (CDCl3) δ / ppm: 26.42 
(C-14), 27.13 (C-16), 27.68 (C-15), 29.15 (C-17), 29.81 (C-
13), 30.93 (C-4), 32.31 (C-10), 41.36 (C-5), 43.14 (C-9), 49.91 
(C-3), 50.62 (C-11), 111.50 (C-2), 114.35 (C-4′), 117.89 (C-
12), 119.10 (C-5′), 124.63 (C-6′), 124.71 (C-1), 139.07 ( C-7), 
143.32 (C-1′), 167.99 (C-2′), 170.86 (C-3′), 196.86 (C-6), 
200.93 (C-8); Anal. Calcd. mass fractions of elements, w / %, 
for C23H25O5 (Mr = 382.45) are: C72.25, H6.54; found: 
C72.29, H6.32. 
 
2,2,5,5-TETRAMETHYL-9-(3',4'-DIHYDROXYPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (2) 
69 %; m.p 147–149 °C; IR(KBr) νmax / cm–1: 3500 (Ar–OH), 
3000 (Ar–H), 1680 (C=O), 1320 (C–O), 1530 (C=O), 1200 
(Ar–OH), 1154 (C–O–C); 13C NMR (CDCl3) δ / ppm: 27.47  
(C-14 and C-16), 29.15 (C-15 and C-17), 29.49 (C-13), 31.46 
(C-4), 32.25 (C-10), 46.46 (C-3 and C-11), 50.77 (C-5 and  
C-9), 114.41 (C-1 and C-7), 115.73 (C-2′), 118.61 (C-6′), 
119.18 (C-5′), 130.93 (C-1′), 143.63 (C-6′); Anal. Calcd. mass 
fractions of elements, w / %, for C23H25O5 (Mr = 382.45): 
C72.23, H6.85; found: C72.35, H6.72. 
 
2,2,5,5-TETRAMETHYL-9-(2'-HYDROXY-3'-
METHOXYPHENYL)-3,4,5,6,7,9-HEXAHYDRO-1H-
XANTHENE-1,8(2H)-DIONE (3) 
93.4 %; m.p 229–231 °C; IR(KBr) νmax / cm–1: 3400 (Ar–OH), 
3000 (Ar–H), 1670 (C=O), 1480 (O–CH3), 1300 (C–O), 1500 
(C=O), 1200 (OH), 1152 (C–O–C); 1H NMR (CDCl3) δ / ppm: 
1.00 (s, 3H, H-17), 1.03 (s, 3H, H-15), 1.13 (s, 6H, H-14 and 
H-16), 1.88–2.75 (m, 9H, H-3, H-5, H-9, H-11 and 2’-OH), 
3.89 (s, 3H, 3’-OCH3), 4.70 (s, 1H, H-13), 6.59 (dd, 1H, J4′5 ′= 
8.3 Hz, J4′6′ = 0.9 Hz, H-4′), 6.76 (dd, 1H, J5′6′ = 8.3 Hz, J4′6′ = 
0.9 Hz, H-6′), 6.95 (t, 1H, J5′6′ = 8.3 Hz, J4′5′ = 8.3 Hz, H-5′); 13C 
NMR (CDCl3) δ / ppm: 27.19 (C-14 and C-16), 27.80 (C-15 
and C-17), 29.12 (C-13), 30.92 (C-4), 32.31 (C-10), 41.58  
(C-3 and C-11), 49.96 (C-5 and C-9), 56.09 (C-7′), 110.45  
(C-4′), 110.90 (C-1), 118.18 (C-7), 119.79 (C-5′), 124.23  
(C-6′ and C-1′), 125.21 (C-1′), 147.14 (C-2′), 147.25 (C-3′), 
168.85 (C-2 and C-12), 200.96 (C-6 and C-8); MS m / z: 397.4 
(M+, 100 %); Anal. Calcd. mass fractions of elements, w / %, 
for C24H28O5 (Mr = 396): C72.7, H7.07; found: C72.64, H7.24. 
 
2,2,5,5-TETRAMETHYL-9-(2'-HYDROXY-5'-NITROPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (4) 
96 %; m.p 205–207 °C; IR(KBr) νmax / cm–1: 3500 (Ar–OH), 
3000 (Ar–H), 1750 (C=O), 1600 (C=C), 1500 (C=O), 1300  
(C–O), 1200 (Ar–OH), 1152(C–O–C), 1250 (NO2); 1H NMR 
(CDCl3) δ / ppm: 0.99 (s, 3H, H-15), 1.032 (s, 3H, H-17), 1.147 
(s, 6H, H-14 and H-16), 1.87–2.73 (m, 9H, H-3, H-11, H-5,  
H-9 and 2′-OH), 4.70 (s, 1H, H-13), 7.11 (d, 1H, J3′4′ = 8.9 Hz, 
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H-3′), 7.94 (d, 1H, J4′,6 ′= 2.5 Hz, H-6′), 8.04 (dd, 1H, H-4′); 13C 
NMR (CDCl3) δ / ppm: 26.98 (C-14 and C-16), 27.82 (C-15 
and C-17), 29.13 (C-13), 31.13 (C-4), 32.28 (C-10), 41.16 (C-
3 and C-11), 49.87 (C-5 and C-9), 110.89 (C-1 and C-7), 
116.37 (C-3′), 123.5 (C-1′), 123.7 (C-4′), 125.9 (C-6′), 144.25 
(C-5′), 155.36 (C-2 and C-12), 167.78 (C-2′), 200.73 (C-6 and 
C-8); MS m / z: 412.4 (M+, 100 %); Anal. Calcd. mass 
fractions of elements, w / %, for C23H25O6N (Mr = 411.45): 
C69.79, H6.32; found: C69.85, H6.38. 
 
2,2,5,5-TETRAMETHYL-9-(2'-FLUOROPHENYL)-3,4,5,6,7,9-
HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (5) 
83 %; m.p 171–174 °C; IR(KBr) νmax / cm–1: 3000 (Ar–H), 
1680 (C=O), 1500 (C=O), 1470(C=C), 1300 (C–O), 1152  
(C–O–C), 1100 (C–F); 1H NMR (CDCl3) δ / ppm: 0.99 (s, 6H, 
H-14 and H-16), 1.15 (s, 6H, H-15 and H-17), 2.25–2.45 (s, 
H-3, H-11, H-5 and H-9), 5.62 (s, 1H, H-13), 6.95 (m, 1H,  
H-5′), 6.99 (m, 1H, H-3′), 7.095 (m, 1H, H-6′), 7.27 (m, 1H, 
H-4′); 13C NMR (CDCl3) δ / ppm: 27.07 (C-14, C-16); 28.88 
(C-15, C-17); 29.45 (C-13); 30.91 (C-4); 31.27 (C-10); 46.387 
(C-3 and C-11), 76.97 (C-5 and C-9), 115.51 (C-1 and C-7), 
118.57 (C-3′), 123.58 (C-1′), 125.5 (C-5′), 127.9 (C-4′), 
129.17 (C-6′), 158.91 (C-2 and C-12), 162.84 (C-2′), 189.46 
(C-6 and C-8); Anal. Calcd. mass fractions of elements, w / %, 
for C23H25O3F (Mr = 368.45): C74.98, H6.84; found: C75.01, 
H6.78. 
 
2,2,5,5-TETRAMETHYL-9-(2'-BROMO-4'-METHYLPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (6) 
89 %; m.p 213–214 °C; IR(KBr) νmax / cm–1: 3000 (Ar–H), 
1750 (C=O), 1604, 1465 (C=C), 1300 (C–O), 1200 (C=O), 
1152 (C–O–C), 750 (C–Br); 1H NMR (CDCl3) δ / ppm: 1.06 (s, 
6H, H-14 and H-16), 1.12 (s, 6H, H-15 and H-17), 2.19–2.53 
(m, 8H, H-3, H-11, H-5 and H-9), 2.27 (s, 3H, 4′-CH3), 5.5 (s, 
1H, H-13), 7.11 (s, 1H, H-3′), 7.15 (d, 1H, H-6′ ), 7.4 (d, 1H, 
H-5′); 13C NMR (CDCl3) δ / ppm: 20.38 (C-7′), 27.01 (C-14 
and C-16), 28.52 (C-15 and C-17), 29.56 (C-13), 31.63 (C-4 
and C-10), 42.78 (C-3 and C-11), 50.82 (C-5 and C-9), 115.80 
(C-1 and C-7), 123.51 (C-2′), 127.83 (C-5′), 129.17 (C-6′), 
134.13 (C-3′), 134.34 (C-4′), 134.94 (C-1′), 137.84 (C-2 and 
C-12), 189.69 (C-6 and C-8); MS m / z: 447.3 (M+, 100 %); 
Anal. Calcd. mass fractions of elements, w/%, for 
C24H27O3Br (Mr = 446.37): C65.01, H6.14; found: C65.25, 
H6.07. 
 
2,2,5,5-TETRAMETHYL-9-(4'-DIMETHYLAMINOPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (7) 
73.6 %; m.p 199–201 °C; IR(KBr) νmax / cm–1: 3000 (Ar–H), 
1680 (C=O), 1465 (C=C), 1400 (C=O), 1300 (C–O), 1158  
(C–O–C), 980 (C–N); 1H NMR (CDCl3) δ / ppm: 1.11 (s, 6H, H-
14 and H-16), 1.24 (s, 6H, H-15 and H-17), 2.22–2.42 (m, 8H, 
H-3, H-11, H-5 and H-9), 2.91 (s, 6H, 7′-N(CH3)2), 5.48 (s, 1H, 
H-13) 6.68 (d, 2H, J2′3 = 8.8 Hz, H-2′ and H-6′), 6.95 (d, 2H, 
H-3′ and H-5′); 13C NMR (CDCl3) δ / ppm: 27.30 (C-14 and C-
16), 29.76 (C-15 and C-17), 31.30 (C-4 and C-10), 32.78 (C-
13), 40.75 (C-7′, N(CH3)2), 46.37 (C-3 and C-11), 46.99 (C-5 
and C-9), 112.69 (C-3′ and C-5′), 115.87 (C-1 and C-7), 
125.49 (C-1′), 127.44 (C-2′ and C-6′), 148.67 (C-4′), 189.21 
(C-2 and C-12), 190.17 (C-6 and C-8); Anal. Calcd. mass 
fractions of elements, w / %, for C25H31O3N (Mr = 393.52): 
C76.30, H7.94; found: C76.34, H7.91. 
 
2,2,5,5-TETRAMETHYL-9-(2',3'-DIMETHOXY-5'-
BROMOPHENYL)-3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-
1,8(2H)-DIONE (8) 
69 %; m.p 185–187 °C; IR(KBr) νmax / cm–1: 3500 (Ar–OH), 
3000 (Ar–O), 1300 (C–O), 1152 (C–O–C), 750 (C–Br); 1H 
NMR (CDCl3) δ / ppm: 1.02 (s, 6H, H-14 and H-16), 1.08 (s, 
6H, H-15 and H-17), 1.88–2.65 (m, 8H, H-3, H-11, H-5 and 
H-9), 3.66 (s, 3H, 2’-OCH3), 3.79 (s, 3H, 3’-OCH3), 3.99 (s, 1H, 
H-13), 4.98 (s, 1H, H-4′), 5.58 (s, 1H, H-6′); 13C NMR (CDCl3) 
δ / ppm: 27.40 (C-14 and C-16), 28.23 (C-15 and C-17), 
31.63 (C-4 and C-10), 32.80 (C-13), 46.38 (C-3 and C-11), 
49.34 (C-5 and C-9), 55.80 (C-7′ and 2’-OCH3), 60.58 (C-8′ 
and 3’-OCH3), 114.66 (C-1 and C-7), 115.94 (C-4′), 123.62 (C-
5′), 124.85 (C-1′), 133.97 (C-6′), 138.46 (C-2′), 153.21 (C-3′), 
189.19 (C-2 and C-12), 196.24 (C-6 and C-8); MS m / z: 389.3 
(M+, 100 %); Anal. Calcd. mass fractions of elements, w / %, 
for C25H29O5Br (Mr = 488.4): C61.35, H5.97; found: C61.32, 
H 6.01. 
 
2,2,5,5-TETRAMETHYL-9-(2',4',6'-TRIMETHOXYPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (9) 
81.5 %; m.p 184–185 °C; IR(KBr) νmax / cm–1: 3065 (Ar–H), 
1700 (C=O), 1600, 1585 (C=C), 1437 (O–CH3), 1300 (C–O), 
1400 (C=O), 1158 (C–O–C); 1H NMR (CDCl3) δ / ppm: 1.02 (s, 
6H, H-14 and H-16), 1.09 (s, 6H, H-15 and H-17), 1.8–2.9 (m, 
9H, H-3, H-11, H-5 and H-9), 3.69–3.76 (sss, 9H, 2’, 4’ and 
6’-OCH3), 5.01 (s, 1H, H-13), 6.2 (m, 2H, H-3′ and H-5′); 13C 
NMR (CDCl3) δ / ppm: 26.87 (C-14 and C-16), 28.07 (C-15 
and C-17), 28.69 (C-13), 31.88 (C-4), 33.14 (C-10), 42.92 (C-
3 and C-11), 48.38 (C-5 and C-9), 55.19 (4’-OCH3), 56.00 (2’ 
and 6’-OCH3), 92.26 (C-3′ and C-5′), 100.01 (C-1′), 112.00 (C-
1 and C-7), 156.87 (C-4′), 159.47 (C-2 and C-12), 163.90 (C-
2′ and C-6′), 196.32 (C-6 and C-8); Anal. Calcd. mass 
fractions of elements, w / %, for C26H32O6 (Mr = 440.5): 
C70.89, H7.32; found: C70.93, H7.24. 
 
2,2,5,5-TETRAMETHYL-9-(2',5'-DIMETHOXYPHENYL)-
3,4,5,6,7,9-HEXAHYDRO-1H-XANTHENE-1,8(2H)-DIONE (10) 
92 %; m.p 181–182 °C; IR(KBr) νmax / cm–1: 3500 (Ar–OH), 
3000 (Ar–H), 1680 (C=O), 1604, 1465 (C=C), 1440 (O–CH3), 
1400 (C=O), 1300 (C–O), 1158 (C–O–C), 860 (trisubstituted 
benzene); 1H NMR (CDCl3) δ / ppm: 1.11 (s, 12H, H-14, H-
16, H-15 and H-17), 1.8–2.45 (m, 8H, H-3, H-11, H-5 and H-
9), 3.67, 3.74 (2s, 6H, 2’ and 5’-OCH3), 5.58 (s, 1H, H-13), 
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6.65 (s, 1H, H-6′), 6.94 (d, 2H, H-3′ and H-4′); 13C NMR 
(CDCl3) δ / ppm: 26.36 (C-14 and C-16), 27.18 (C-15 and C-
17), 29.40 (C-13), 31.22 (C-4 and C-10), 42.79 (C-3 and C-
11), 48.84 (C-5 and C-9), 55.47 (5’-OCH3), 55.91 (2’-OCH3), 
111.16 (C-4′), 112.21 (C-1 and C-7), 116.32 (C-3′), 128.01 (C-
1′), 151.42 (C-2′), 153.03 (C-5′), 189.12 (C-6 and C-8); MS Ž 
m / z: 412.4 (M+, 100 %); Anal. Calcd. mass fractions of 
elements, w / %, for C25H30O5 (Mr = 411.5): C73.15, H7.37; 
found: C73.28, H7.19. 
Evaluation of Antioxidant Activity by 
DPPH Method 
The free radical scavenging activity of synthesized 2,2,5,5-
tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-
1,8(2H)-diones was evaluated using a stable radical, 1,1-
diphenyl-2-picrylhydrazyl (DPPH·) in methanol solution 
described in literature.[19] 
 When determining the antioxidant activity by using 
DPPH method, the absorbance of the 0.2 mM methanol 
solution of the test substance was mixed with the same 
ratio of 0.2 mM DPPH solution, representing the absorb-
ance of the sample (AA (t)). The control solution is a mixture 
of methanol and DPPH. The measurement was done  
30 minutes after the addition of DPPH at 517 nm. In order 
to determine the concentration of a compound that inhibits 
DPPH activity by 50 % (EC50), a dilution series was made for 
each sample individually, and from the calibrated curves 
the concentration ratio and percent inhibition were deter-
mined by EC50. The inhibition percentage (%) of radical 
scavenging activity was calculated by using the equation 1: 
 
 C A
C
(0) ( )
% inhibition 100
(0)
−
= ×
A A t
A
 (1) 
 
where Ac (0) is the absorbance of control at t = 0 and AA (t) 
is the absorbance of antioxidant at t = 30 min. All measure-
ments were done in triplicate.[20,21] 
Antimicrobial Activity 
Antibacterial activity was tested by the diffusion method 
against Bacillus subtilis ATCC 6633, Staphylococcus aureus 
ATCC 6538P, Escherichia coli ATCC 9027 and Pseudomonas 
aeruginosa ATCC 15442, while antifungal activity was 
tested against Candida albicans ATCC 1023 and Saccharo-
myces cerevisiae ATCC 9763. Test samples were dissolved 
in 99.5% dimethyl sulfoxide (DMSO) to obtain a 1 mg/mL 
stock solutions which were then applied to Müller-Hinton 
and Sabouraud nutritious bases. The inhibition zones for 
bacteria were measured in millimetres at the end of an in-
cubation period of 18 h at 37 °C, and for fungal strains after 
48 h at 25 °C. Compounds that showed good antimicrobial 
activity tested by the diffusion method were further tested 
by dilution method. For this, Casein soya bean digest broth 
(Triptic soya bujon) was used. As referent compounds chlo-
ramphenicol and fluconazole are used in concentration of 
500 µg mL–1. Test solution of the compound was prepared, 
followed by formation of a series of 12 dilutions with liquid 
nutritious base. After the incubation for 24 h, the last tube 
with no growth of microorganisms was taken to represent 
minimum inhibitory concentration (MIC) expressed in mg 
mL–1. The concentrations of the prepared solutions were in 
range 0.5–0.00024 mg mL–1. 
Cell Culturing for Antiproliferative 
Evaluation 
The cell lines HeLa (cervical carcinoma), SW620 (colorectal 
adenocarcinoma, metastatic), hepatocellular carcinoma 
(HEpG2), lung carcinoma cells (A549) and mouse embryo 
fibroblast cell line (3T3), were cultured as monolayers and 
maintained in Dulbecco's modified Eagle medium (DMEM, 
Lonza, Austria) supplemented with 10 % fetal bovine  
serum (FBS), 2 mM L-glutamine, 100 U mL–1 penicillin and 
100 μg mL–1 streptomycin in a humidified atmosphere with 
5 % CO2 at 37 °C. Trypan blue solution was used to 
determine cell viability using an automatic cell counter 
(Countess, Invitrogen, USA). Morphology was determined 
under light microscope (Axio Vision-Zeiss, Germany). 
Proliferation Assays 
A panel of adherent tumour cell lines were inoculated onto 
a series of standard 96-well microtiter plates on day 0, at 
5000 cells per well. Test agents were then added in five, 10-
fold dilutions (0.01 µM to 100 µM) and incubated for fur-
ther 72 h. Working dilutions were freshly prepared on the 
day of testing in the growth medium. The solvent (DMSO) 
was also tested for eventual inhibitory activity by adjusting 
its concentration to be the same as in the working concen-
trations (DMSO concentration never exceeded 0.1 %). After 
72 h of incubation, the cell growth rate was evaluated by 
performing the MTT assay. End-point absorbance was 
measured at 570 nm. Each test point was performed in 
quadruplicate in three individual experiments. Experimen-
tally determined absorbance values were transformed into 
a cell percentage growth (PG) using the formulas proposed 
by NIH and described previously.[22] This method directly 
relies on control cells at the day of assay because it com-
pares the growth of treated cells with the growth of un-
treated cells in control wells on the same plate. The results 
are therefore a percentile difference from the calculated 
expected value. The IC50 and LC50 values for each compound 
were calculated from dose-response curves using linear re-
gression analysis by fitting the mean test concentrations 
that give PG values above and below the reference value. 
If, however, all of the tested concentrations produce PGs 
exceeding the respective reference level of effect (e.g. PG 
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value of 50) for a given cell line, the highest tested concen-
tration is assigned as the default value (in the screening 
data report that default value is preceded by a ">" sign). 
 
RESULTS AND DISCUSSION 
Synthesis 
The synthesis of 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-
hexahydro-1H-xanthene-1,8(2H)-diones (1–10) was 
assumed to proceed via formation of a Knoevenagel 
product (A), which by addition of second molecule gave the 
Michael adduct intermediate (B) and was followed by 
cyclization (Figure 1). An α,α'-bis(arylidene)cycloalkanone 
(A) was firstly condensed with dimedone to afford the 
intermediate (B) by addition of second molecule of 
dimedone where this step can be regarded as a Michael 
addition. Then the intermediate B was cyclized by 
nucleophilic attack of the hydroxy group on the C=C moiety 
and 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-
xanthene-1,8(2H)-diones (1-10) were afforded.[19] 
 According to described procedure we synthesized 
ten new 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-
1H-xanthene-1,8(2H)-dione derivatives (1–10), that are 
structural analogues with different substituents at aryl ring 
(Table 1). 
Structural Characterisation of 
Compounds 1–10 
In all IR spectra of synthesized 2,2,5,5-tetramethyl-9-aryl-
3,4,5,6,7,9 -hexahydro-1H-xanthene-1,8(2H)-dione derivatives 
there are absorption bands characteristic for xanthene 
structure; absorption bands at 1600-1680 cm–1 come from 
the C=O group and 1152 cm–1 band from C–O–C vibration. 
Also, in all IR spectra of synthesized xanthene compounds, 
there are bands at 1300 cm–1, characteristic for C–O 
stretching, and deformation vibrations of the OH group at 
1200 cm–1. The IR spectra of the synthesized xanthene 
compounds differ in absorption bands that come from the 
corresponding substituent attached to the phenyl ring. For 
compounds with trisubstituted benzene ring in the struc-
ture there are visible characteristic bands at 860 cm–1 
(compounds 8 and 9). For compound with bromine in the 
structure there is visible characteristic band at 750 cm–1 
from C–Br stretching, while for methoxy substituted deriv-
atives (compounds 3, 8, 9 and 10), IR spectra contain bands 
between 1200 and 1450 cm–1 characteristic for stretching 
of O–CH3. Compound with dimethylamino group (com-
pound 7) shows band at 1440 cm–1 which originates from 
N–CH3 stretching. Synthesized compounds with hydroxy 
groups as substituents (compounds 1, 2, 3, 4) on IR spectra 
showed bands at 2500–3400 cm–1. In IR spectra of com-
pound with fluor as substituent (compound 5) there is visi-
ble band at 1100 cm–1 from C–F streching. 
 The 1H NMR spectra of synthesized 2,2,5,5-tetrame-
thyl-9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione 
derivatives contain signals characteristic for 2,2,5,5-tetra-
methyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione 
structure. Thus, in all spectra are visible singlets in the 
range 1.0–1.25 ppm from H-14, H-15, H-16 and H-17 atoms. 
Also, all spectra possess multiplets (m) in the range 1.88–
2.75 ppm from H-3, H-5, H-9 and H-11 atoms, and in the 
range 4.7–6.04 ppm singlet originating from H-13 atom. 
Compounds with methoxy group as substituent on the ben-
zene ring possess singlet at 3.7–3.9 ppm which is character-
istic for protons from the methoxy group (compounds 3, 8, 
9). Compound with dimethylamino group substituted on 
the benzene ring (compound 7) on 1H NMR spectra has a 
singlet at 2.91-3.10 ppm, derived from the protons of the 
dimethylamino group. Compound 6, with methyl group in 
the structure, reveals a singlet at 2.27 ppm which comes 
from the protons of the methyl group. 
 13C NMR spectra of synthesized 2,2,5,5-tetramethyl-
9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione 
OO OHO OO
Ar
O
HO
O Ar
OO
O
O
O O
Dimedone
DABCO
O
ArH
-H2O
R1
R2
R3
R4
R5
1-10
Michael
 addition
cyclization
-H2O
1st
 molecule (A) 2nd
 molecule
DABCO
(B)  
Figure 1. Mechanism of synthesis of 2,2,5,5-tetramethyl-9-
aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-diones.[19] 
 
 
Table 1. Substituents at phenyl ring of synthesized 
compounds. 
Compound R1 R2 R3 R4 R5 
1 OH OH H H H 
2 H OH OH H H 
3 OH OCH3 H H H 
4 OH H H NO2 H 
5 F H H H H 
6 Br H CH3 H H 
7 H H N(CH3)2 H H 
8 OCH3 OCH3 H Br H 
9 OCH3 H OCH3 H OCH3 
10 OCH3 H H OCH3 H 
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derivatives show characteristic. All spectra possess signals 
in the range of 26.4–29.9 ppm from the carbon atoms of 
the methyl groups (C-14, C-15, C-16, C-17), also at 30.1–
32.02 ppm signals from C-4 and C-10 atoms and at 32.72 
ppm signals of the C-13 atom. 
Antioxidant Activity 
For synthesized 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-
hexahydro-1H-xanthene-1,8(2H)-dione antioxidant acivity 
was determinated by DPPH method. For this test, 0.2 mM 
methanolic solutions for each of the compounds were 
used. As a standard in the determination of antioxidant ac-
tivity trolox was used which at the same concentration as the 
synthesized derivatives showed an inhibition of 84.54 %. 
 In order to determine the exact concentration in 
which the activity of the DPPH reagent was inhibited by  
50 % (EC50), dilution series were individually made and for 
each dilution the absorbances were measured at 517 nm. 
The results of antioxidant activity are shown in Table 2. 
 According to the obtained results compound 2 (with 
two hydroxy groups substituted on phenyl ring in positions 
3' and 4') has shown the best antioxidant effect with EC50 
of 0.017 mM. The higher scavenging activity of compound 
2 could be attributed to the formation of two radicals on 
hydroxy groups both of which are stabilized by resonance. 
Similarly compound 1 also has two hydroxy groups on phe-
nyl ring, but in positions 2' and 3' and its EC50 of 0.075 mM 
indicates antioxidant potency lower than of the compound 
2, so we can conclude that position of hydroxy groups has 
significant effect on the activity. This difference in potency 
could be due to the difference in the stability of the radi-
cals. Also, in literature good antioxidant activity is described 
for dibenzoxanthene and xanthene-11-one derivatives 
against hydroxy radicals which correlates well with our 
results.[23,24] 
Antimicrobial Activity 
Microbiological activity was determinated by diffusion and 
dilution method on four strains of bacteria and two strains 
of fungi. The tests were carried out on gram negative 
bacteria Escherichia coli ATCC 9027 and Pseudomonas 
aeruginosa ATCC 15442, and gram positive bacteria 
Staphylococcus aureus ATCC 6538P and Bacillus subtilis 
ATCC 6051. The antifungal activity of synthetized xanthene 
compounds was tested against fungi Candida albicans ATCC 
 
Table 2. Absorbances, percentage of inhibition and EC50 of 
0.2 mM solution of synthesized compounds. 
Compound Absorbance  
(t = 30 min) 
% Inhibition EC50 / mM 
1 0.429 68.74 0.075 
2 0.178 87.03 0.017 
3 0.510 62.83 0.13 
4 0.595 58.86 0.16 
5 0.527 61.59 0.135 
6 0.528 61.52 0.130 
7 0.321 76.60 0.03 
8 0.503 63.34 0.129 
9 0.383 72.08 0.04 
10 0.440 67.93 0.095 
Control 1.372; t = 0   
Trolox 0.212 84.54 0.018 
  
Table 3. Results of antibacterial activity by diffusion method. 
Compound 
Zone of inhibition / mm 
Escherichia coli 
(ATCC 9027) 
Pseudomonas aeruginosa 
(ATCC 15442)  
Staphylococcus aureus 
(ATCC 6538P) 
Bacillus subtilis 
(ATCC 6051) 
1 9 10 16.5 14 
2 11 12 14.5 12 
3 8 11 11 13 
4 11 14 13 16 
5 11 15 11 18.5 
6 12 16 12.5 19.5 
7 10.5 14 16 20 
8 20 13.5 19 13 
9 11 15 14 19 
10 12 14 15 18 
Chloramphenicol 23.5 20 24 22.5 
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1023 and Saccharomyces cerevisiae ATCC 9763 As standard 
in the study, chloramphenicol (for antibacterial testing) and 
fluconazole (for the examination of antifungal activity) 
were used. 
 The results of antimicrobial acivity of synthesized 
compounds by diffusion method are shown in Table 3 and 
Table 4. 
 Results showed that the best antibacterial activity 
against Escherichia  coli ATCC 9027 and Staphylococcus 
aureus  ATCC 6538P possesses compound 8. The best 
activity against Pseudomonas aeruginosa ATCC 15442 
showed compound 6 and against Bacillus subtilis ATCC 
6051 compounds 6 and 7. Also, compound 6 showed the 
best antifungal activity with zone of inhibition of 18.5 mm 
against Candida albicans ATCC 1023 and 18 mm against 
Saccharomyces cerevisiae ATCC 9763. 
 Described in vitro antibacterial activity of 
tetrahydrobenzoxanthene-11-one derivative against 
Pseudomonas strains suggests that antibacterial activity 
increased with increasing number of hydroxy groups in 
molecule.[25] In our research the best activity against 
Pseudomonas strain showed compound with bromine in 
structure, while compounds with hydroxy groups possess 
weak antibacterial activity against same bacterium. The 
results of antimicrobial activity by dilution method are 
shown in Table 5 and Table 6. 
 
Table 4. Results of antifungal activity by diffusion method. 
Compound 
Zone of inhibition / mm 
Candida albicans 
(ATCC 1023) 
Saccharomyces cerevisiae 
(ATCC 9763) 
1 13.5 14 
2 11 16.5 
3 12.5 16 
4 12 12 
5 14.5 14.5 
6 18.5 18 
7 18 16.5 
8 15 16 
9 16 14.5 
10 16 14 
Fluconazole 20.5 21 
  
Table 5. Results of antibacterial activity by dilution method. 
Compound 
MIC / mg mL–1 
Escherichia coli 
(ATCC 9027) 
Pseudomonas aeruginosa 
(ATCC 15442)  
Staphylococcus aureus 
(ATCC 6538P) 
Bacillus subtilis 
(ATCC 6051) 
1 2.50 2.50 1.25 2.50 
2 1.25 2.50 1.25 1.25 
3 5.00 2.50 2.50 2.50 
4 1.25 1.25 1.25 1.25 
5 1.25 1.25 1.25 1.25 
6 1.25 1.25 1.25 1.25 
7 2.50 1.25 1.25 2.50 
8 0.625 1.25 0.625 0.625 
9 2.50 1.25 1.25 1.25 
10 2.50 1.25 1.25 1.25 
Chloramphenicol 0.078 0.313 0.01 0.01 
 
 
Table 6. Results of antifungal activity by dilution method. 
Compound 
MIC / mg mL–1 
Candida albicans 
(ATCC 1023) 
Saccharomyces cerevisiae 
(ATCC 9763) 
1 2.50 1.25 
2 2.50 1.25 
3 2.50 1.25 
4 2.50 1.25 
5 2.50 1.25 
6 2.50 1.25 
7 2.50 1.25 
8 2.50 1.25 
9 2.50 0.625 
10 2.50 1.25 
Fluconazole 0.313 0.313 
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 By dilution method, the best antibacterial activity 
against Escherichia  coli ATCC 9027, Staphylococcus aureus 
ATCC 6538P and Bacillus subtilis ATCC 6051 showed 
compound 8 with Minimum Inhibitory Concentration (MIC) 
of 0.625 mg mL–1. 
 All synthesized compounds showed weak antifungal 
activity by dilution method against tested fungal strains; 
the best activity was of compound 9 against Saccharomyces 
cerevisiae ATCC 9763 with MIC of 0.625 mg mL–1. 
Antiproliferative Activity 
Antiproliferative activity of synthesized compounds were 
tested by MTT test and results are showed in Table 7. 
 Antitumor effect of synthetized 2,2,5,5-tetramethyl-
9-aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-diones 
showed that only some of the synthesized compounds af-
fected tested tumor cells. According to the metastatic car-
cinoma of colon (SW620) compounds 2, 6, 8, 9 and 10 
showed activity where compound 6 with IC50 of 0.87 μM 
was the best one. Other synthesized 2,2,5,5-tetramethyl-9-
aryl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione de-
rivatives in the tested concentrations have not shown anti-
proliferative activity against SW620 cell lines. Against the 
cells of hepatocellular carcinoma (HEpG2), active were 
compounds 1, 2, 6, 8, 9 and 10,  where the best activity 
again showed compound 6 with IC50 of 6.0 μM. Compounds 
2, 3, 6, 8, 9 and 10 showed activity against the cervical ad-
enocarcinoma (HeLa); compound 6 with IC50 of 5.6 μM was 
again the most effective at inhibiting the tumor cells 
growth. High activity of xanthene compounds against tu-
mor cells has been described in literature.[26,27] Comparing 
antiproliferative activity of xanthene derivatives with other 
research[28] where similar 9-aryl-3,4,6,7,9,10-hexahydroac-
ridine-1,8-diones, with nitrogen instead of oxygen in the 
main moiety, were tested and showed ineffective against 
tested cells, we can conclude that xanthene ring is im-
portant for antiproliferative activity. The worst antiprolifer-
ative effect of the synthesized compounds was reported 
against lung carcinoma cells (A549), where only com-
pounds 2 and 9 showed antiproliferative effect in the 
tested concentrations (compound 9 being better with IC50 
of 57.0 μM). 
 
CONCLUSION 
Ten new 2,2,5,5-tetramethyl-9-aryl-3,4,5,6,7,9-hexahydro-
1H-xanthene-1,8(2H)-dione derivatives were synthesized 
and tested for antioxidant, antimicrobial and antiprolifera-
tive activities. The best antioxidant compound was 2,2,5,5-
tetramethyl-9-(3',4'-dihydroxyphenyl)-3,4,5,6,7,9-hexahydro-
1H-xanthene-1,8(2H)-dione (2) with two hydroxy groups 
substituted on phenyl ring in positions 3' and 4' indicating 
the importance of the substitutents position since the 
isomere, compound 1, also bearing 2 hydroxy groups in 
positions 2' and 3' had almost 20 % lower inhibition effect. 
The best antimicrobial activity of all synthesized com-
pounds showed compounds with bromine, 6 and 8 (which 
also possesses two methoxy groups in positions 2' and 3') 
indicating that bromine in the molecule might play im-
portant role in inhibiting growth factors of these microor-
ganisms. On the other side, similar molecules with methoxy 
group (9 and 10), but without the bromine, showed some-
what lesser activity. The best antiproliferative activity 
against three tumour cell lines (HeLa, SW620 and HEpG2) 
showed again compound with bromine, 2,2,5,5-tetrame-
thyl-9-(2'-bromo-4'-methylphenyl)-3,4,5,6,7,9-hexahydro-
1H-xanthene-1,8(2H)-dione (6) indicating that bromine was 
responsible for inhibiting the proliferation of the tumor 
cells. The obtained results indicate the need for further syn-
thesis of compounds of similar structures, as well as the 
need to test this group of compounds for other phar-
macological activities, for which xanthenes are known to 
possess. This would give a more complete picture of the 
pharmacological effects of these agents. 
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